87 related articles for article (PubMed ID: 29931775)
1. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Radocha J; Maisnar V; Pour L; Špička I; Minařík J; Szeligová L; Pavlíček P; Jungová A; Krejčí M; Pika T; Straub J; Brožová L; Stejskal L; Heindorfer A; Jindra P; Kessler P; Mikula P; Sýkora M; Wróbel M; Jarkovský J; Hájek R
Cancer Med; 2018 Aug; 7(8):4132-4145. PubMed ID: 29931775
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
Sandecka V; Popkova T; Stork M; Maisnar V; Minarik J; Jungova A; Pavlicek P; Stejskal L; Pospisilova L; Heindorfer A; Obernauerova J; Gregora E; Sykora M; Ullrychova J; Wrobel M; Kessler P; Jelinek T; Kunovszki P; Bathija S; Gros B; Wilbertz S; Cai Q; Lam A; Spicka I
Blood Cancer J; 2023 Sep; 13(1):153. PubMed ID: 37752128
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Mao X; Yan W; Mery D; Liu J; Fan H; Xu J; Xu Y; Sui W; Deng S; Zou D; Du C; Yi S; van Rhee F; Barlogie B; Shaughnessy JD; Anderson KC; Zhan F; Qiu L; An G
Am J Hematol; 2024 Apr; 99(4):523-533. PubMed ID: 38247315
[TBL] [Abstract][Full Text] [Related]
4. Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China.
Ren L; Ren Y; Yang Y; Wang W; Xu T; Wang Y; Xu J; Maihemaiti A; Lan T; Li P; Zhou C; Wang P; Liu P
Hematology; 2023 Dec; 28(1):2277503. PubMed ID: 38018564
[TBL] [Abstract][Full Text] [Related]
5. Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review.
Hájek R; Gonzalez-McQuire S; Szabo Z; Delforge M; DeCosta L; Raab MS; Bouwmeester W; Campioni M; Briggs A
BMJ Open; 2020 Jul; 10(7):e034209. PubMed ID: 32665382
[TBL] [Abstract][Full Text] [Related]
6. Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data.
Sinyavskaya L; Meche A; Faucher A; Hlavacek P; Johnson SMA; DiBonaventura M; Vekeman F; Ren J; Schepart A
Curr Med Res Opin; 2024 May; 40(5):789-801. PubMed ID: 38523576
[No Abstract] [Full Text] [Related]
7. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing.
Li JR; Arsang-Jang S; Cheng Y; Sun F; D'Souza A; Dhakal B; Hari P; Huang Q; Auer P; Li Y; Urrutia R; Zhan F; Shaughnessy JD; Janz S; Dong J; Cheng C
Blood Cancer J; 2024 Mar; 14(1):38. PubMed ID: 38443358
[TBL] [Abstract][Full Text] [Related]
8. Use of the Second Revision of the International Staging System for prognostic stratification of multiple myeloma patients in real-world clinical practice and the importance of sub-groups, including age.
Uesugi Y; Ikeda D; Fukumoto A; Tabata R; Miura D; Narita K; Takeuchi M; Matsue K
Haematologica; 2024 May; 109(5):1593-1597. PubMed ID: 38031801
[No Abstract] [Full Text] [Related]
9. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making.
Gonzalez-McQuire S; Dimopoulos MA; Weisel K; Bouwmeester W; Hájek R; Campioni M; Bennison C; Xu W; Pantiri K; Hensen M; Terpos E; Knop S
MDM Policy Pract; 2019; 4(1):2381468318814253. PubMed ID: 30729167
[No Abstract] [Full Text] [Related]
10. Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.
Ballas L; Ailawadhi S; Narang M; Gasparetto CJ; Lee HC; Hardin JW; Durie BGM; Toomey K; Omel J; Wagner LI; Abonour R; Terebelo HR; Joshi P; Yu E; Liu L; Rifkin RM; Jagannath S
Pract Radiat Oncol; 2024; 14(2):e141-e149. PubMed ID: 37984714
[TBL] [Abstract][Full Text] [Related]
11. Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.
Nakaya A; Shibayama H; Uoshima N; Yamamura R; Yoshioka S; Imada K; Shimura Y; Hotta M; Matsui T; Kosugi S; Hanamoto H; Uchiyama H; Yoshihara S; Fuchida SI; Onda Y; Tanaka Y; Ohta K; Matsuda M; Kanda J; Yoko A; Kiyota M; Kawata E; Takahashi R; Fukushima K; Tanaka H; Yagi H; Takakuwa T; Hosen N; Ito T; Shimazaki C; Takaori-Kondo A; Kuroda J; Matsumura I; Hino M
Leuk Res Rep; 2023; 20():100395. PubMed ID: 38076634
[TBL] [Abstract][Full Text] [Related]
12. Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications.
Schoeller K; Ihorst G; Reinhardt H; Holler M; Scheubeck S; Herget G; Wäsch R; Engelhardt M
Haematologica; 2024 Apr; 109(4):1279-1284. PubMed ID: 38031759
[No Abstract] [Full Text] [Related]
13. The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma.
de Daniel A; Rodríguez-Lobato LG; Tovar N; Cibeira MT; Moreno DF; Oliver-Caldés A; Isola I; Lozano E; Bladé J; Rosiñol L; Fernández de Larrea C
Hemasphere; 2024 May; 8(5):e76. PubMed ID: 38716147
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Gammopathies and CKD Progression: An Unfinished Story.
Chowdhury R; Gupta S
Clin J Am Soc Nephrol; 2024 Mar; 19(3):280-282. PubMed ID: 38170512
[No Abstract] [Full Text] [Related]
15. Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202).
Cho H; Kim K; Yoon SE; Jung SH; Lee JJ; Moon JH; Cho HJ; Lee HS; Kang KW; Kim SY; Eom HS; Mun YC; Park YH; Yoon SS; Do YR; Lee WS; Min CK; Yoon DH
Hemasphere; 2024 Jan; 8(1):e33. PubMed ID: 38434530
[No Abstract] [Full Text] [Related]
16. The genomic features associated with high-risk multiple myeloma.
Walker BA; Morgan GJ
Oncotarget; 2018 Oct; 9(84):35478-35479. PubMed ID: 30464803
[No Abstract] [Full Text] [Related]
17. How I treat the young patient with multiple myeloma.
Gandolfi S; Prada CP; Richardson PG
Blood; 2018 Sep; 132(11):1114-1124. PubMed ID: 29967130
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in cytogenetic characterization of multiple myeloma.
Saxe D; Seo EJ; Bergeron MB; Han JY
Int J Lab Hematol; 2019 Feb; 41(1):5-14. PubMed ID: 29971938
[TBL] [Abstract][Full Text] [Related]
19. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies F; Rosenthal A; Wang H; Qu P; Hoering A; Samur M; Towfic F; Ortiz M; Flynt E; Yu Z; Yang Z; Rozelle D; Obenauer J; Trotter M; Auclair D; Keats J; Bolli N; Fulciniti M; Szalat R; Moreau P; Durie B; Stewart AK; Goldschmidt H; Raab MS; Einsele H; Sonneveld P; San Miguel J; Lonial S; Jackson GH; Anderson KC; Avet-Loiseau H; Munshi N; Thakurta A; Morgan G
Leukemia; 2019 Jan; 33(1):159-170. PubMed ID: 29967379
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of multiple myeloma in Taiwan, a population based study.
Tang CH; Liu HY; Hou HA; Qiu H; Huang KC; Siggins S; Rothwell LA; Liu Y
Cancer Epidemiol; 2018 Aug; 55():136-141. PubMed ID: 29957398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
